ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 652

Identification of Eat-2 As a Lupus Susceptibility Gene in New Zealand Black (NZB) Mice That Regulates Dendritic Cell Function

Nafiseh Talaei1 and Joan E. Wither2, 1Genetics and Development, Toronto Western Research Institute, Toronto, ON, Canada, 21E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, dendritic cells and genetics, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: We have previously shown that B6 mice with an introgressed homozygous NZB chromosome (c) 1 interval (70 to 100 cM) develop high titres of antinuclear antibodies and severe glomerulonephritis (GN), with approximately 40% of the mice dying by 8 months age.  Using subcongenic mice with shorter intervals in this region we found that T cell and dendritic cell (DC) defects, derived from several genetic loci, synergize to convert the preclinical disease in c1(96-100) mice to fatal GN in c1(70-100) mice through expansion of pro-inflammatory T cell subsets.  EAT-2, an adapter molecule in the SLAM signaling pathway that is located in the 70-96 cM region, has a promoter polymorphism in NZB mice that is predicted to lead to decreased expression.  In this study we examine whether altered expression of this molecule leads to the abnormal DC function observed in these mice.

Methods: Expression levels of EAT-2 were evaluated in bone marrow derived DC from c1 congenic and B6 mice using qRT-PCR and Western blots.  siRNAs targeting EAT-2 gene were introduced into B6 and c1 congenic DC. Subsequently, naïve OVA-specific TCR transgenic (OTII) T cells from B6 and c1 congenic mice were isolated and co-cultured with EAT-2 silenced or scrambled control treated DC in the presence of OVA peptide.  In parallel DC were stimulated with anti-CD40 before and after knock-down of EAT-2. Production of cytokines (IL-12, IL-6, IFN-g) by DC and T cells were analyzed by flow cytometry. 

Results: Expression of EAT-2 was reduced by ~70% in DC from c1(70-100) mice as compared to c1(96-100) and B6 mice. Silencing of the EAT-2 gene in DC from B6 and congenic mice resulted in increased production of IL-12 as compared to scrambled control and was associated with increased differentiation of OVA-specific T cells from both B6 and c1 congenic mice to a Th1 phenotype. Knock-down of EAT-2 in DC from all strains of  mice did not affect IL-6 production when co-cultured with B6.OTII T cells, however augmented IL-6 production was seen for c1(96-100) and c1(70-100) DC when co-cultured with naïve T cells from c1 congenic mice. This was accompanied by somewhat enhanced production of IL-21, but not IL-17, by c1 congenic OTII T cells.  SLAM/SLAM homotypic interactions inhibit production of IL-12 and IL-6 by CD40L-activated DCs.  Consistent with a role for EAT-2 in this inhibition, knock-down of EAT-2 resulted in increased production of IL-12 by CD40-stimulated B6 and c1(96-100) DC.  This was recapitulated in c1(70-100) DC, which demonstrated increased production of IL-12, and a trend to increased production of IL-6, as compared to B6 or c1(96-100) DC following CD40 stimulation.

Conclusion: EAT-2 negatively regulates cytokine production in DC downstream of the SLAM molecules and a genetic polymorphism leading to low levels of EAT-2 in c1(70-100) mice may contribute to the increased production of IL-12 we have previously observed for their DC.


Disclosure:

N. Talaei,
None;

J. E. Wither,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-eat-2-as-a-lupus-susceptibility-gene-in-new-zealand-black-nzb-mice-that-regulates-dendritic-cell-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology